Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 12:44 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 1,144 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Grippe Clear all

Conditions: Viral Pneumonia
Interventions: SNG001, Placebo; Drug
Lead sponsor: Synairgen Research Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 5
States / cities: Atlanta, Georgia • Chicago, Illinois • Detroit, Michigan + 2 more

Conditions: Flu
Interventions: the H3N2 M2SR monovalent influenza vaccine, Placebo; Biological · Other
Lead sponsor: FluGen Inc; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Kidney Transplant, Immunology, Immunosuppression
Interventions: Not listed
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 59 Years
Enrollment: 97 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Influenza A Virus, H5N1 Subtype
Interventions: VRC-AVIDNA036-00-VP, Monovalent Influenza Subunit Virion (Inactive H5N1) Vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Immune Response
Interventions: High Dose Influenza vaccine, Adjuvanted Influenza vaccine, Standard Dose Influenza vaccine, Recombinant Influenza vaccine; Biological
Lead sponsor: Marshfield Clinic Research Foundation; Other
Eligibility: 65 Years to 74 Years
Enrollment: 179 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Marshfield, Wisconsin

Conditions: Influenza
Interventions: Trivalent influenza vaccine GSK 138842A, Fluarix; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 2
States / cities: Miami, Florida • Lenexa, Kansas

Conditions: Influenza
Interventions: H3N2v MN 2010/AA ca live attenuated influenza vaccine (LAIV), H3N2v inactivated subvirion influenza vaccine, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 6 Years to 26 Years
Enrollment: 1 participant
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2016
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Influenza
Interventions: Peramivir, Placebo; Drug
Lead sponsor: BioCryst Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 96
States / cities: Millbrook, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 80 more

Conditions: Reminder Systems, Influenza Vaccines
Interventions: Reminders; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 6 Months to 17 Years
Enrollment: 25,531 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Influenza
Interventions: Synbiotic AKSB; Biological
Lead sponsor: Mayo Clinic; Other
Eligibility: 65 Years and older
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Healthy
Interventions: Fluad® and Afluria® vaccination; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 49 Years
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Influenza
Interventions: Vaccine administration by a pharmacist, Unmet vaccination needs identified and met, Vaccination forecast review and patient education; Biological · Behavioral
Lead sponsor: American Pharmacists Association Foundation; Other
Eligibility: 18 Years and older
Enrollment: 1,080 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 8
States / cities: Belfair, Washington • Cheney, Washington • Eatonville, Washington + 5 more

Conditions: Inflammatory Bowel Disease (IBD)
Interventions: Standard dose Influenza vaccine (SDIV), High dose influenza vaccine (HDIV); Biological
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 64 Years
Enrollment: 81 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Influenza
Interventions: Not listed
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: Not listed
Enrollment: 1,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Influenza
Interventions: Influenza Virus Type A H3N2 Challenge; Biological
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 49 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Influenza
Interventions: Influenza Vaccine, recombinant Hemagglutinin; Biological
Lead sponsor: Protein Sciences Corporation; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 459 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2005
U.S. locations: 3
States / cities: Rochester, New York • Cincinnati, Ohio • Charlottesville, Virginia

Conditions: HIV Infections, H1N1 Influenza Virus
Interventions: Influenza A (H1N1) 2009 monovalent vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 4 Years to 25 Years
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 35
States / cities: Birmingham, Alabama • Alhambra, California • La Jolla, California + 25 more

Conditions: Zika, Influenza
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 5,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Influenza, Human
Interventions: MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV), Licensed MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine (aTIV-1), MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine Containing the Alternate B Strain (aTIV-2); Biological
Lead sponsor: Seqirus; Industry
Eligibility: 65 Years and older
Enrollment: 1,778 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 20
States / cities: Mobile, Alabama • Anaheim, California • Redding, California + 17 more

Conditions: Influenza
Interventions: AVX502, Placebo; Biological
Lead sponsor: AlphaVax, Inc.; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 216 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Influenza, Human
Interventions: Influenza Vaccine; Biological
Lead sponsor: PharmaJet, Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 985 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 6
States / cities: Huntsville, Alabama • San Diego, California • Melbourne, Florida + 3 more

Conditions: H3N2 Influenza
Interventions: Placebo, Sing2016 M2SR H3N2; Other · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 6 Months to 17 Years
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 4
States / cities: Iowa City, Iowa • Baltimore, Maryland • Durham, North Carolina + 1 more

Conditions: Influenza
Interventions: mRNA-1010, mRNA-1010.4, mRNA-1010.6; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 270 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 10
States / cities: Hollywood, Florida • Miami, Florida • Lenexa, Kansas + 7 more

Conditions: COVID-19, Influenza
Interventions: GRIP Electronic Diagnostic Chip, Laboratory-based nucleic acid amplification tests (NAATs); Device · Diagnostic Test
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Rochester, Minnesota

Search by objective public record fields.

Phase 2 Study of Inhaled SNG001 in Mechanically Ventilated Patients With Respiratory Viral Infection

Safety and Immunogenicity Study of H3N2 M2SR Monovalent Influenza Vaccine in Healthy Volunteers

Protective Immunity Project 02

An Open-Label, Randomized Phase I Study in Healthy Adults of the Safety and Immunogenicity of Prime-Boost Intervals With Monovalent Influenza Subunit Virion (H5N1) Vaccine, A/Indonesia/05/2005 (Sanofi Pasteur, Inc.) Administered Alone or Following Re...

Open-Label Influenza Vaccine Evaluation

Safety and Immune Response Study of GSK Biologicals' Influenza Virus Vaccine 1388442A Compared With Fluarix

Evaluating the Safety and Immunogenicity of a Live Attenuated Virus Vaccine to Prevent Influenza H3N2v Disease

Intramuscular Peramivir in Subjects With Uncomplicated Acute Influenza

Centralized IIS-based Reminder/Recall to Increase Childhood Influenza Vaccination Rates_2nd Trial in Colorado

Safety of Synbiotics as Adjuvant to Influenza Vaccine in Elderly

WU 345: Immune Responses to Adjuvanted and Non-adjuvanted Seasonal Influenza Vaccines in the Lymphoid Tissues.

Project IMPACT Immunizations (IMProving America's Communities Together)

Trial of High Dose vs. Standard Dose Influenza Vaccine in Inflammatory Bowel Disease Patients

Influenza IMPRINT Cohort: Defining the Impact of Initial Influenza Exposure on Immunity in Infants

Influenza Human Challenge Model

Immunogenicity and Safety of Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy Adults

Safety of and Immune Response to an H1N1 Influenza Virus Vaccine in HIV Infected Children and Youth

Screening for LID Clinical Studies Unit Healthy Volunteer Protocols

Phase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults

A Phase 1/2 Clinical Trial of an Alphavirus Replicon Vaccine for Influenza

Inactivated Influenza Via Jet Injection

Assess the Safety and Immunogenicity of One or Two Doses of Sing2016 M2SR H3N2 Influenza Vaccine

Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults

A Study of the GRIP Influenza and SARS-CoV-2 POC Assays